Myeloproliferative neoplasier (MPN)
Myeloproliferative neoplasier (MPN)
Sist oppdatert: 21.12.2023
Mer informasjon
Utgiver: Helsedirektoratet
Versjon: 1.0
Tidligere versjoner
Kopier lenke til dette emnet
Kopiert
Foreslå endringer/gi kommentarer
Dette kapittelet omtaler diagnostikk og behandling av polycytemia vera, essensiell trombocytose, prefibrotisk myelofibrose, primær myelofibrose, sekundær myelofibrose og uklassifiserbare myeloproliferative tilstander.
Mens kronisk myelogen leukemi er omtalt i eget kapittel, omtales ikke kronisk nøytrofil leukemi og kronisk eosinofil leukemi i handlingsprogrammet for maligne blodsykdommer
Kapittelet er oppdatert i henhold til siste 5. utgave av WHO klassifikasjon (2022) for diagnostikk. I tillegg til 5. utgave av WHO klassifikasjonen foreligger det fra 2022 også et alternativt klassifikasjonssystem, International Consensus Classification (ICC). For de myeloproliferative sykdommene er det ingen forskjeller mellom WHO og ICC er klassifikasjonene, og nytt klassifiseringssystem har derfor ingen betydning for dette handlingsprogrammet.
Fortsatt er det viktig å bruke de diagnostisk kriteriene til diagnostikken av de ulike diagnosene, både hoved- og bikriterier.
Kapittelet er også oppdatert ihht. ny retningslinjer for risikostratifisering og behandling av MPN.
Referanser
Alvarez-Larrán, A., Sant'Antonio, E., Harrison, C., Kiladjian, J. J., Griesshammer, M., Mesa, R., ... Barbui, T. (2021). Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.
The Lancet. Haematology,
8(9), e658-e665.
Barbui, T., De Stefano, V., Carobbio, A., Iurlo, A., Alvarez-Larran, A., Cuevas, B., ... Mascarenhas, J. (2021). Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.
Leukemia,
35(10), 2989-2993.
Birgegård, G., Besses, C., Griesshammer, M., Gugliotta, L., Harrison, C. N., Hamdani, M., ... Kiladjian, J. J. (2018). Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
Haematologica,
103(1), 51-60.
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., ... Tefferi, A. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Blood,
113(13), 2895-901.
Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., ... Tefferi, A. (2011). DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Journal of Clinical Oncology,
29(4), 392-7.
Gisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H. M., ... Petrides, P. E. (2013). Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Blood,
121(10), 1720-8.
Guglielmelli, P., Carobbio, A., Rumi, E., De Stefano, V., Mannelli, L., Mannelli, F., ... Barbui, T. (2020). Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
Blood cancer journal,
10(2), 21.
Harrison, C. N., & Robinson, S. E. (2011). Myeloproliferative disorders in pregnancy.
Hematology/oncology clinics of North America,
25(2), 261-75, vii.
Harrison, C. N., Schaap, N., Vannucchi, A. M., Kiladjian, J. J., Jourdan, E., Silver, R. T., ... Mesa, R. A. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
American journal of hematology,
95(6), 594-603.
Kröger, N., Bacigalupo, A., Barbui, T., Ditschkowski, M., Gagelmann, N., Griesshammer, M., ... Barosi, G. (2023). Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
The Lancet. Haematology
Kröger, N., Wolschke, C., & Gagelmann, N. (2023). How I treat transplant-eligible patients with myelofibrosis.
Blood,
142(20), 1683-1696.
Landtblom, A. R., Bower, H., Andersson, T. M., Dickman, P. W., Samuelsson, J., Björkholm, M., ... Hultcrantz, M. (2018). Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Leukemia,
32(10), 2203-2210.
Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., ... Tefferi, A. (2015). Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
JAMA oncology,
1(5), 643-51.
Pardanani, A., Tefferi, A., Masszi, T., Mishchenko, E., Drummond, M., Jourdan, E., ... Harrison, C. (2021). Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
British Journal of Haematology,
195(2), 244-248.
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., ... Tefferi, A. (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Blood,
115(9), 1703-8.
WHO Classification of Tumours Editorial Board (2022).
Haematolymphoid tumours. [nettdokument - beta versjon ahead of print]. Lyon: International Agency for Research on Cancer. Hentet 2023 fra
https://tumourclassification.iarc.who.int/welcome/
- Gå til avsnitt
- Referanser
Lukk
